Damora Therapeutics, Inc. (DMRA) Stock Forecast
DMRA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.90 / 5 from 10 analysts
- Price target
- $46.89 average of analyst targets
- Upside to target
- +154.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.52
- 52-week range
- $4.95 – $34.14
DMRA analyst ratings
10 analystsNumber of analysts at each rating.
DMRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DMRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.43 | −$0.53 | −$0.37 | — | — | 4 |
| Current fiscal year (2026) | −$1.90 | −$2.34 | −$1.60 | −$3.98 | +66.9% | 4 |
| Next fiscal year (2027) | −$2.17 | −$2.59 | −$1.59 | −$1.90 | −14.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DMRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 7 |
DMRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DMRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.40 | −$0.43 | −$0.43 | −$0.43 | +10.1% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.75 | −$1.75 | −$1.89 | −$1.89 | −$1.90 | +8.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$2.08 | −$2.08 | −$2.14 | −$2.14 | −$2.17 | +4.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DMRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DMRA beat in 4 of 8.
What analysts expect from DMRA
10 analysts cover Damora Therapeutics; their consensus rating is strong buy (4.90 on a 1–5 scale, where 5 is a strong buy). The average price target is $46.89, 154.3% above the latest close of $18.44. Analysts expect earnings of −$1.90 per share for 2026, +66.9% from a year earlier. For 2027 the average estimate is −$2.17 per share. Damora Therapeutics beat the EPS estimate in 4 of the last 8 quarters.
Related: DMRA income statement, DMRA key metrics, DMRA chart. See the DMRA stock overview for the latest quote and news.
DMRA forecast FAQ
What is Damora Therapeutics's price target?
The average analyst price target for Damora Therapeutics is $46.89, 154.3% above the latest close of $18.44.
Is Damora Therapeutics a buy, hold or sell?
Of 10 analysts covering Damora Therapeutics, 9 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Damora Therapeutics's EPS forecast?
Analysts forecast −$1.90 per share for 2026 (range −$2.34 to −$1.60); for 2027 the estimate is −$2.17.
When does Damora Therapeutics report earnings?
Damora Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.52.
Does Damora Therapeutics usually beat earnings estimates?
Damora Therapeutics reported EPS at or above the analyst estimate in 4 of the last 8 quarters.